(Q43692814)

English

Analysis of biochemical bone markers as prognostic factors for survival in patients with hormone-resistant prostate cancer and bone metastases

scientific article published in February 2004

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Analysis of biochemical bone markers as prognostic factors for survival in patients with hormone-resistant prostate cancer and bone metastases (English)

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Pierpaolo Correale

8

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

author name string

Roberto Petrioli

1

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Stefania Rossi

2

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Mario Caniggia

3

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Daniele Pozzessere

4

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Simona Messinese

5

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Marianna Sabatino

6

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Stefania Marsili

7

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Francesco Salvestrini

9

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Antonio Manganelli

10

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Guido Francini

11

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

language of work or name

0 references

publication date

1 February 2004

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

63

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

321-326

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.09.044

7 January 2021

The current state of hormonal therapy for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.09.044

7 January 2021

Weekly chemotherapy in advanced prostatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.09.044

7 January 2021

Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.09.044

7 January 2021

Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.09.044

7 January 2021

Weekly epirubicin in patients with hormone-resistant prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.09.044

7 January 2021

Weekly low-dose docetaxel in advanced hormone-resistant prostate cancer patients previously exposed to chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.09.044

7 January 2021

Bone remodeling markers in the detection of bone metastases in prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.09.044

7 January 2021

Biochemical markers for the detection of bone metastasis in patients with prostate cancer: diagnostic efficacy and the effect of hormonal therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.09.044

7 January 2021

Urinary calcium excretion in the monitoring of bone metastases from prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.09.044

7 January 2021

Androgen priming and chemotherapy in advanced prostate cancer: evaluation of determinants of clinical outcome

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.09.044

7 January 2021

Analysis of prognostic factors in men with metastatic prostate cancer. Uro-Oncology Group of Northern Alberta

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.09.044

7 January 2021

Original article: Prognostic factors in hormone-resistant progressing cancer of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.09.044

7 January 2021

Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.09.044

7 January 2021

Treatment of bone metastases with dichloromethylene bisphosphonate.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.09.044

7 January 2021

Plasma osteopontin: associations with survival and metastasis to bone in men with hormone-refractory prostate carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.09.044

7 January 2021

Inability of bone turnover marker as a strong prognostic indicator in prostate cancer patients with bone metastasis: comparison with the extent of disease (EOD) grade

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.09.044

7 January 2021

Type I collagen degradation product (ICTP) gives information about the nature of bone metastases and has prognostic value in prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.09.044

7 January 2021

Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.09.044

7 January 2021

Immunoassay and immunohistology studies of chromogranin A as a neuroendocrine marker in patients with carcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.09.044

7 January 2021

Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.09.044

7 January 2021

Importance of continued testicular suppression in hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.09.044

7 January 2021

Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.09.044

7 January 2021

Identifiers

10.1016/J.UROLOGY.2003.09.044

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

release_rb5gl7522bdx5jmqhbi6cfuaju

1 reference

https://api.fatcat.wiki/v0/release/rb5gl7522bdx5jmqhbi6cfuaju

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

25 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43692814&oldid=2102621925"